Keytruda (pembrolizumab) - Merck (MSD)
Keytruda: Data from KEYNOTE-242 trial for adjuvant TNBC in 2026 or later (Merck (MSD)) - Jun 21, 2019 - Investor Day: Data from P3 KEYNOTE-630 trial (NCT03833167) for high-risk locally advanced cutaneous squamous cell carcinoma in 2026 or later 
Clinical data • P3 data
https://investors.merck.com/events-and-presentations/default.aspx
 
Jun 21, 2019
 
 
26add9d8-c26a-41dc-8723-d4450667ba43.jpg